Do analysts rate BRAI or DMAA?

Braiin currently has a consensus target price of $10.00, indicating a potential upside of 110.08%. Given Braiin's stronger consensus rating and higher probable upside, equities analysts clearly believe Braiin is more favorable than Drugs Made In America Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Braiin 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, BRAI or DMAA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Braiin N/A N/A N/A N/A N/A Drugs Made In America Acquisition N/A N/A N/A N/A N/A

Is BRAI or DMAA more profitable?

Company Net Margins Return on Equity Return on Assets Braiin N/A N/A N/A Drugs Made In America Acquisition N/A N/A N/A

Does the media favor BRAI or DMAA?

In the previous week, Braiin had 24 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 27 mentions for Braiin and 3 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 0.82 beat Braiin's score of 0.11 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Braiin 5 Very Positive mention(s) 6 Positive mention(s) 7 Neutral mention(s) 5 Negative mention(s) 3 Very Negative mention(s) Neutral Drugs Made In America Acquisition 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DMAA or VYX?

NCR Voyix has a consensus price target of $12.20, indicating a potential upside of 70.01%. Given NCR Voyix's stronger consensus rating and higher possible upside, analysts plainly believe NCR Voyix is more favorable than Drugs Made In America Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NCR Voyix 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher earnings & valuation, DMAA or VYX?

NCR Voyix has higher revenue and earnings than Drugs Made In America Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Drugs Made In America Acquisition N/A N/A N/A N/A N/A NCR Voyix $2.69B 0.37 $62M $0.40 17.94

Does the media prefer DMAA or VYX?

In the previous week, NCR Voyix had 2 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 5 mentions for NCR Voyix and 3 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 0.82 beat NCR Voyix's score of 0.52 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Drugs Made In America Acquisition 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NCR Voyix 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TUYA or DMAA?

Tuya currently has a consensus target price of $3.69, suggesting a potential upside of 113.91%. Given Tuya's stronger consensus rating and higher probable upside, equities analysts clearly believe Tuya is more favorable than Drugs Made In America Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tuya 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, TUYA or DMAA?

Tuya has higher revenue and earnings than Drugs Made In America Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tuya $321.79M 2.91 $57.89M $0.11 15.68 Drugs Made In America Acquisition N/A N/A N/A N/A N/A

Does the media prefer TUYA or DMAA?

In the previous week, Tuya and Tuya both had 3 articles in the media. Drugs Made In America Acquisition's average media sentiment score of 0.82 beat Tuya's score of 0.15 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tuya 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Drugs Made In America Acquisition 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer DJCO or DMAA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daily Journal Corp. (S.C.) 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, DJCO or DMAA?

Daily Journal Corp. (S.C.) has higher revenue and earnings than Drugs Made In America Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daily Journal Corp. (S.C.) $87.70M 10.14 $112.14M -$8.22 N/A Drugs Made In America Acquisition N/A N/A N/A N/A N/A

Does the media prefer DJCO or DMAA?

In the previous week, Daily Journal Corp. (S.C.) and Daily Journal Corp. (S.C.) both had 3 articles in the media. Drugs Made In America Acquisition's average media sentiment score of 0.82 beat Daily Journal Corp. (S.C.)'s score of 0.80 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daily Journal Corp. (S.C.) 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Drugs Made In America Acquisition 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MGIC or DMAA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Magic Software Enterprises 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, MGIC or DMAA?

Magic Software Enterprises has higher revenue and earnings than Drugs Made In America Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Magic Software Enterprises $603.22M 1.41 $36.88M $0.81 21.46 Drugs Made In America Acquisition N/A N/A N/A N/A N/A

Drugs Made In America Acquisition (DMAA) Competitors

$10.88 +0.02 (+0.14%)

Closing price 10:53 AM Eastern

Extended Trading

$10.89 +0.02 (+0.17%)

As of 04:39 PM Eastern

Compare

DMAA vs. BRAI, VYX, TUYA, DJCO, and MGIC

Should you buy Drugs Made In America Acquisition stock or one of its competitors? Drugs Made In America Acquisition's main competitors and comparable companies include Braiin (BRAI), NCR Voyix (VYX), Tuya (TUYA), Daily Journal Corp. (S.C.) (DJCO), and Magic Software Enterprises (MGIC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Drugs Made In America Acquisition compare to Braiin?

Braiin (NASDAQ:BRAI) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Braiin currently has a consensus target price of $10.00, indicating a potential upside of 110.08%. Given Braiin's stronger consensus rating and higher probable upside, equities analysts clearly believe Braiin is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Braiin	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Braiin	N/A	N/A	N/A	N/A	N/A
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Braiin	N/A	N/A	N/A
Drugs Made In America Acquisition	N/A	N/A	N/A

In the previous week, Braiin had 24 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 27 mentions for Braiin and 3 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 0.82 beat Braiin's score of 0.11 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Braiin	5 Very Positive mention(s)	6 Positive mention(s)	7 Neutral mention(s)	5 Negative mention(s)	3 Very Negative mention(s)	Neutral
Drugs Made In America Acquisition	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Braiin beats Drugs Made In America Acquisition on 4 of the 5 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to NCR Voyix?

Drugs Made In America Acquisition (NASDAQ:DMAA) and NCR Voyix (NYSE:VYX) are both small-cap technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

NCR Voyix has a net margin of 2.53% compared to Drugs Made In America Acquisition's net margin of 0.00%. NCR Voyix's return on equity of 11.23% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Drugs Made In America Acquisition	N/A	N/A	N/A
NCR Voyix	2.53%	11.23%	2.61%

NCR Voyix has a consensus price target of $12.20, indicating a potential upside of 70.01%. Given NCR Voyix's stronger consensus rating and higher possible upside, analysts plainly believe NCR Voyix is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NCR Voyix	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

97.0% of NCR Voyix shares are held by institutional investors. 0.9% of Drugs Made In America Acquisition shares are held by insiders. Comparatively, 0.5% of NCR Voyix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, NCR Voyix had 2 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 5 mentions for NCR Voyix and 3 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 0.82 beat NCR Voyix's score of 0.52 indicating that Drugs Made In America Acquisition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Drugs Made In America Acquisition	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NCR Voyix	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

NCR Voyix has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A
NCR Voyix	$2.69B	0.37	$62M	$0.40	17.94

Summary

NCR Voyix beats Drugs Made In America Acquisition on 9 of the 11 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Tuya?

Tuya (NYSE:TUYA) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap technology companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Tuya has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tuya	$321.79M	2.91	$57.89M	$0.11	15.68
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A

Tuya currently has a consensus target price of $3.69, suggesting a potential upside of 113.91%. Given Tuya's stronger consensus rating and higher probable upside, equities analysts clearly believe Tuya is more favorable than Drugs Made In America Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tuya	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.5% of Tuya shares are owned by institutional investors. 2.1% of Tuya shares are owned by insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Tuya has a net margin of 20.16% compared to Drugs Made In America Acquisition's net margin of 0.00%. Tuya's return on equity of 6.74% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tuya	20.16%	6.74%	5.96%
Drugs Made In America Acquisition	N/A	N/A	N/A

In the previous week, Tuya and Tuya both had 3 articles in the media. Drugs Made In America Acquisition's average media sentiment score of 0.82 beat Tuya's score of 0.15 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tuya	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Drugs Made In America Acquisition	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tuya beats Drugs Made In America Acquisition on 9 of the 10 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Daily Journal Corp. (S.C.)?

Daily Journal Corp. (S.C.) (NASDAQ:DJCO) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

51.2% of Daily Journal Corp. (S.C.) shares are owned by institutional investors. 0.1% of Daily Journal Corp. (S.C.) shares are owned by company insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daily Journal Corp. (S.C.)	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Drugs Made In America Acquisition has a net margin of 0.00% compared to Daily Journal Corp. (S.C.)'s net margin of -11.63%. Drugs Made In America Acquisition's return on equity of 0.00% beat Daily Journal Corp. (S.C.)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daily Journal Corp. (S.C.)	-11.63%	-3.11%	-2.24%
Drugs Made In America Acquisition	N/A	N/A	N/A

In the previous week, Daily Journal Corp. (S.C.) and Daily Journal Corp. (S.C.) both had 3 articles in the media. Drugs Made In America Acquisition's average media sentiment score of 0.82 beat Daily Journal Corp. (S.C.)'s score of 0.80 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daily Journal Corp. (S.C.)	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Drugs Made In America Acquisition	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Daily Journal Corp. (S.C.) has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daily Journal Corp. (S.C.)	$87.70M	10.14	$112.14M	-$8.22	N/A
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Drugs Made In America Acquisition beats Daily Journal Corp. (S.C.) on 5 of the 8 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Magic Software Enterprises?

Magic Software Enterprises (NASDAQ:MGIC) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap technology companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Magic Software Enterprises has a net margin of 6.61% compared to Drugs Made In America Acquisition's net margin of 0.00%. Magic Software Enterprises' return on equity of 16.28% beat Drugs Made In America Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Magic Software Enterprises	6.61%	16.28%	8.96%
Drugs Made In America Acquisition	N/A	N/A	N/A

24.7% of Magic Software Enterprises shares are held by institutional investors. 4.5% of Magic Software Enterprises shares are held by company insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Drugs Made In America Acquisition had 3 more articles in the media than Magic Software Enterprises. MarketBeat recorded 3 mentions for Drugs Made In America Acquisition and 0 mentions for Magic Software Enterprises. Drugs Made In America Acquisition's average media sentiment score of 0.82 beat Magic Software Enterprises' score of 0.00 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company	Overall Sentiment
Magic Software Enterprises	Neutral
Drugs Made In America Acquisition	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Magic Software Enterprises	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Drugs Made In America Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Magic Software Enterprises has higher revenue and earnings than Drugs Made In America Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Magic Software Enterprises	$603.22M	1.41	$36.88M	$0.81	21.46
Drugs Made In America Acquisition	N/A	N/A	N/A	N/A	N/A

Summary

Magic Software Enterprises beats Drugs Made In America Acquisition on 7 of the 9 factors compared between the two stocks.

Get Drugs Made In America Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DMAA vs. The Competition

Export

Metric	Drugs Made In America Acquisition	Software Industry	Technology Sector	NASDAQ Exchange
Market Cap	$264.01M	$16.48B	$30.18B	$12.92B
Dividend Yield	N/A	3.42%	2.76%	22.89%
P/E Ratio	N/A	143.01	78.65	25.28
Price / Sales	N/A	1,272.98	581.86	78.55
Price / Cash	N/A	47.10	49.48	53.04
Price / Book	N/A	8.70	7.72	5.92
Net Income	N/A	$431.49M	$768.63M	$381.04M
7 Day Performance	0.32%	-2.26%	-4.32%	-4.41%
1 Month Performance	0.42%	-3.18%	-3.49%	-7.30%
1 Year Performance	5.58%	-0.27%	163.41%	-5.04%

Drugs Made In America Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DMAA Drugs Made In America Acquisition	0.4757 of 5 stars	$10.88 +0.1%	N/A	+5.4%	$264.01M	N/A	N/A	2	Positive News High Trading Volume
BRAI Braiin	2.8429 of 5 stars	$4.63 -12.8%	$10.00 +116.0%	N/A	$954.19M	N/A	N/A	5	Trending News High Trading Volume
VYX NCR Voyix	3.7598 of 5 stars	$6.71 -1.9%	$12.40 +84.8%	-37.2%	$925.07M	$2.69B	16.78	13,500	Analyst Forecast
TUYA Tuya	4.6009 of 5 stars	$1.70 -1.5%	$3.69 +117.7%	-30.6%	$918.02M	$321.79M	15.41	1,441	Dividend Announcement Short Interest Decrease
DJCO Daily Journal Corp. (S.C.)	0.4956 of 5 stars	$656.44 +0.5%	N/A	+52.3%	$904.57M	$97.65M	N/A	424

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DMAA) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Drugs Made In America Acquisition (DMAA) Competitors

DMAA vs. BRAI, VYX, TUYA, DJCO, and MGIC

How does Drugs Made In America Acquisition compare to Braiin?

Summary

How does Drugs Made In America Acquisition compare to NCR Voyix?

Summary

How does Drugs Made In America Acquisition compare to Tuya?

Summary

How does Drugs Made In America Acquisition compare to Daily Journal Corp. (S.C.)?

Summary

How does Drugs Made In America Acquisition compare to Magic Software Enterprises?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAA vs. The Competition

Drugs Made In America Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Drugs Made In America Acquisition (DMAA) Competitors

DMAA vs. BRAI, VYX, TUYA, DJCO, and MGIC

How does Drugs Made In America Acquisition compare to Braiin?

Do analysts rate BRAI or DMAA?

Which has stronger earnings & valuation, BRAI or DMAA?

Is BRAI or DMAA more profitable?

Does the media favor BRAI or DMAA?

Summary

How does Drugs Made In America Acquisition compare to NCR Voyix?

Is DMAA or VYX more profitable?

Do analysts prefer DMAA or VYX?

Do insiders & institutionals believe in DMAA or VYX?

Does the media prefer DMAA or VYX?

Which has higher earnings & valuation, DMAA or VYX?

Summary

How does Drugs Made In America Acquisition compare to Tuya?

Which has better earnings and valuation, TUYA or DMAA?

Do analysts prefer TUYA or DMAA?

Do institutionals and insiders have more ownership in TUYA or DMAA?

Is TUYA or DMAA more profitable?

Does the media prefer TUYA or DMAA?

Summary

How does Drugs Made In America Acquisition compare to Daily Journal Corp. (S.C.)?

Do institutionals & insiders have more ownership in DJCO or DMAA?

Do analysts prefer DJCO or DMAA?

Is DJCO or DMAA more profitable?

Does the media prefer DJCO or DMAA?

Which has higher valuation and earnings, DJCO or DMAA?

Summary

How does Drugs Made In America Acquisition compare to Magic Software Enterprises?

Is MGIC or DMAA more profitable?

Do insiders & institutionals hold more shares of MGIC or DMAA?

Does the media favor MGIC or DMAA?

Do analysts recommend MGIC or DMAA?

Which has higher valuation and earnings, MGIC or DMAA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DMAA vs. The Competition

Drugs Made In America Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools